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Abstract
Background The purpose of this prospective study was to
evaluate the clinical diagnostic value of iodine-124 (
124I)-
positron emission tomography (PET) in patients with
advanced differentiated thyroid carcinoma (DTC) and to
compare the
124I-PET imaging results with the
131I whole-
body scan (WBS).
Materials and methods Twenty patients with histologically
proven advanced DTC (including T4, extra-nodal tumour
growth, or distant metastases) underwent diagnostic
131I-
WBS,
124I-PET scan, and post-treatment
131I-WBS 4 months
after ablation. The findings on the
124I-PET were compared
with the findings on the diagnostic and post-therapeutic
131I-WBS and were also correlated with radiologic and/or
cytological investigations.
Results
124I-PET vs diagnostic
131I-WBS. Eleven patients
showed uptake on the
124I-PET. Only 3 of these 11 patients
also showed uptake on the diagnostic
131I scan, but the
uptake was more clearly visible and the abnormalities were
more extensive on the
124I-PET.
124I-PET vs post-treatment
131I-WBS. Eleven patients showed uptake on the
124I-PET,
which was also visible on the post-treatment scan in nine
patients; in the other two patients, no uptake was observed
on the post-treatment scan and no anatomical localisation
could be confirmed. Two patients showed only uptake on
the post-treatment scan without uptake on the
124I-PET: in
one, the uptake was confirmed by MRI, and in the other, no
anatomical localisation was found. In seven patients, no
uptake was observed on both the scans.
Conclusion
124I-PET proved to be a superior diagnostic
tool as compared to low-dose diagnostic
131I scans and
adequately predicted findings on subsequent high-dose
post-treatment
131I scans.
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Introduction
Papillary and follicular thyroid cancer are the most frequent
histological types of thyroid cancer (85–90%) [1, 2]. Total
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Hamilton, Canadathyroidectomy with or without lymph node dissection is the
initial therapy, followed by radioactive iodine therapy.
In the routine follow-up of low-risk patients, diagnostic
131I whole-body scanning (WBS) is not recommended in
the recently published guidelines [3]( http://www.british-
thyroid-association.org/draft_thyca_23.12.06.pdf; http://
www.oncoline.nl/uploaded/docs/Schildkliercarcinoom/
schildklier%20ebro/richtl ijn%20schildklier.pdf), but is still
considered to be valuable in the follow-up of the high-risk
patients. Measurement of the serum level of thyroglobulin
(Tg), under recombinant human thyroid-stimulating hor-
mone (rhTSH) stimulation or suppression, and ultrasonog-
raphy have gained a more central role in monitoring for
recurrent thyroid cancer [3, 4–7]( http://www.british-thyroid-
association.org/draft_thyca_23.12.06.pdf). In patients with
increasing or elevated Tg, a blind treatment with high-dose
131I can be applied, followed by a post-treatment
131I scan
which also serves as a diagnostic tool [21]. However, with
this strategy, unnecessary high radiation exposure and
high TSH level must be taken into account especially in
patients who subsequently have no
131I uptake on their
post-treatment scan. Improvement of diagnostic imaging for
the detection of recurrent or metastatic disease and a better
(anatomical) localisation, e.g. using advanced imaging
technique such as
124I-positron emission tomography
(PET)/CT would allow more selective application of
131I
therapy and might avoid unnecessary high-dose treatments.
Several iodine isotopes such as
123I,
125I,
131I play an
important role in nuclear medicine, both for diagnostic
purposes and for therapy. Iodine-124 is a positron emitting
isotope and therefore suitable PET imaging. Its half-life is
4.2 days with a very complex decay scheme leading to
extra non- or partially annihilation radiation coincidence
detection [8, 9]. Approximately 23% of the desintegrations
results in positron emissions.
While the radioisotopes
123I and especially
131I are used
on a wide scale in diagnosis and treatment of all thyroid
disorders,
124I has received little attention. This isotope
would allow thyroid cancer imaging using the high-
resolution PET technique [8, 10]. Iodine-124 has so far
mainly been used for dosimetry or thyroid volume measure-
ments [10–16]. However, the recent development of
combined PET/CT scanners may increase clinical applica-
tion in thyroid cancer patients, as detailed anatomical
information is combined with the location of iodine positive
tissue [17]. Iodine-124 has recently been applied for staging
of differentiated thyroid cancer, as reported in a few case
reports and small series, with promising results [17–19].
However, the diagnostic value of
124I-PET imaging as
compared to (low- and high-dose)
131I scintigraphy has to
be further investigated.
Iodine-124 PET may be able to detect recurrent or
residual disease in differentiated thyroid carcinoma (DTC)
with a higher sensitivity than the conventional (diagnostic)
131I scans because of the higher spatial resolution. In this
way,
124I-PET imaging could possibly be a useful diagnos-
tic tool during the follow-up of DTC patients. Therefore,
we have performed a pilot study in the early treatment
phase of thyroid cancer to get an impression of the
diagnostic potential of
124I-PET for detection and staging
of advanced DTC. We compared the
124I-PET imaging
results with the diagnostic and post-treatment
131I-WBS.
Materials and methods
Twenty patients with histologically proven advanced DTC,
including extrathyroidal tumour growth (T4), extra-nodal
tumour growth or distant metastasis (M1), were examined
in this study. These patients had undergone (near) total
thyroidectomy. Four to 6 weeks after surgery, diagnostic
131I-WBS after 37 MBq of
131I was obtained, followed by
an ablative dose of 5,550 MBq
131I. Post-treatment WBS
was obtained after 10 days. At the time of ablation, serum
Tg and Tg antibodies (TgAb) levels were also determined.
All 20 studied patients underwent diagnostic
131I-WBS,
124I-PET scan and post-treatment
131I-WBS 4 months after
ablation therapy (Fig. 1). The Tgoff levels (under TSH
stimulation after thyroid hormone withdrawal or after
rhTSH injection) were also measured just before the
administration of the diagnostic low-dose
131I. The Medical
Ethics Committee of University Medical Center Groningen
approved the study protocol, and all patients gave written
informed consent.
Tg was measured by immunoradiometric assay (Brahms,
Henningsdorf, Germany), with a functional sensitivity (i.e.
the Tg concentration with a vital capacity of 20%) of
0.3 ng/ml as determined by the laboratory. Thyroglobulin
antibodies (TgAb) were detected by both immunoradio-
metric assay (Brahms, Henningsdorf, Germany) with a
cutoff of 60 U/ml and by immunoluminometric assay
(Abbott, Hoofddorp, Netherlands) on the Architect i 2000
platform (Abbott) with a cutoff of 4.1 U/ml. Both cutoff
concentrations were determined by Brahms and Abbott,
respectively. In 19 patients, the Tg level was determined
after thyroid hormone withdrawal and in one patient after
rhTSH due to poor physical condition (Table 1).
Tracer
124I-sodium iodide solution was obtained from Ritverc
Isotope Products, St. Petersburg, Russia and was imported
by I.D.B. Holland BV (Baarle-Nassau, The Netherlands).
Radiochemical purity using instant thin layer chromatogra-
phy and radionuclide purity using germanium (HP-Ge)
detector were tested before release according to standard
Eur J Nucl Med Mol Imaging (2008) 35:958–965 959radiopharmaceutical procedures. Before use, the solution
was filtered using a Millipore bacterial filter (0.22 μm) and
diluted with sterile saline. A sterility test was performed on
each batch, but data were only available after administra-
tion due to the length of the test procedure (7 days).
PET scanning
Diagnostic
124I-PET imaging was performed 24 h after
intravenous administration of 74 MBq of
124I[ 17]. A
Siemens PET camera (Exact HR+, Knoxville, TN, USA)
was used for imaging. The patient was positioned in the
scanner, and a standard clinical whole-body PET study was
performed in 2D ETTE mode over seven to eight positions
Fig. 1 The diagram showed a schematic course of the investigations
performed 4 months after ablation
Table 1 Patient characteristics and imaging results
Pt Age,
sex
TNM Tgoff
(ng/ml)
TSH
(mU/l)
124I-PET Pt
131I-WBS Dx
131I-
WBS
Validation
1 59M pT1N0M1 48 50 CV, pelvis
+++
CV, pelvis
+++
CV,
pelvis +
MR cv: p, MRI pelvis:p
2 67F fT4N1M1 201 48 Neck, thyroid
bed +++,
lung ++
Neck, thyroid
bed +++
lung ++
Neck
++
CT lung: no abnormal lesions, MRI neck: p
3 85M fT4N0M1 2.6
a 0.01
a Skull, CV,
pelvis +++
CV+++ CV + Skull: p, MR cv: p
b
4 48F pT4N1M0 49 77 Neck ++ Neck ++ – MRI:neck: p
5 74F pT4N1M0 <0.30 44 Neck ++ Neck ++ – MRI:neck: p
6 74M fT2N0M1 691 >200 Neck/SC +++ Neck/SC,
pelvis +++
– MRI pelvis: p
b
7 73F fT4N1M0 105 56 Neck/thyroid
bed +
Neck/thyroid
bed ++
– US neck/FNAC: p
8 18F pT4N1M1 <0.30 51 Pelvis ++ Pelvis + – MRI pelvis:p
9 39M pT4N1M0 85 75 Neck +++ Neck +++ – MRI neck: p
10 73F pT4N1M0 3 43 Neck + –– US neck and FNAC: inconclusive, FDG PET: n
11 59M fT3N0M1 1680 73 Femur
prosthesis
++
–– MRI pelvis/femur : reactive tissue around
the femur prosthesis; FDG PET: lesions
in costae and pelvis
12 73M pT3N0M1 <0.30 33 – skull ++ – MRI skull: p, FDG PET: n
13 67M pT4N0M0 <0.30 142 – pelvis + – X-pelvis: n, bone scan: n
14 42F pT4N1M0 15 81 ––– US neck and FNAC: n, FDG PET: n
15 49F pT4N0M0 18 66 ––– US neck and FNAC: n, FDG PET: n
16 59M pT4NxM0 2.8 76 ––– MRI neck, US neck and FNAC: n, FDG PET: n
17 68M pT2N0M1 14 44 ––– US neck/FNAC: n, FDG PET and CT: lung lesions
18 79F fT4NxM0 1.6 53 ––– MRI neck: p, US neck: lymph node not accessible for
FNA, FDG PET: n
19 71F fT4N0M0 0.54 36 ––– –
20 37M pT1N1bM0 <0.30 95 ––– –
p Papillar, f follicular, Pt
131I-WBS post-treatment
131I-WBS, Dx
131I-WBS diagnostic
131I-WBS, CV cervical vertebrae, SC sternal clavicular, −
not visible, + just visible, ++ visible, +++ clearly visible, n negative, p positive, FNAC fine needle aspiration cytology, FDG-PET
fluorodeoxyglucose positron emission tomography
arhTSH stimulated
bIn these two patients, no additional radiologic imaging of the neck (no. 3) and pelvis (no. 6) was performed to confirm the findings on the PET
and
131I-WBS due to poor physical condition and due to the lack curative therapeutic options
960 Eur J Nucl Med Mol Imaging (2008) 35:958–965(from the upper thigh up until the top of the skull) of 5-min
emission and 3-min transmission, standard energy window
setting of 350–650 keV. Images were reconstructed with
attenuation-weighted OSEM, two iterations and eight
subsets. The total time needed for the scan was approxi-
mately 60 min.
In the initial four patients, the
124I-PET images were
repeated 96 h after
124I administration (thus, 72 h after
therapeutic dose of
131I) using the same acquisition settings
as after 24 h. Narrowing of the energy window (425–650 or
460–562 keV, 3D mode) for
124I-PET imaging during high-
dose
131I therapy to reduce the effects of γ-rays (364,
637 keV) of
131I and
124I (602 keV) and to improve image
quality, as described in the phantom study (and clinical
application in one thyroid cancer patient) by Lubberink et
al. [20], was not possible in our institution due to technical
reasons, e.g. camera characteristics. The 96-h
124I-PET
images were very noisy and blurred and were excluded
from the study. This poor image quality could partially be
explained by the poor statistics due to the very low
radioactivity left in the body after 96 h and partially by
technical reasons as described above.
Data analysis
The
131I-WBS and
124I-PET scans were visually interpreted
by two independent, experienced nuclear medicine physi-
cians (HTP, PLJ). The findings on the
124I-PET scans were
compared with the findings on the diagnostic and post-
therapeutic
131I-WBS. Correlation with radiologic imaging
(US, CT, MRI) and/or cytological (fine needle aspiration
cytology, FNAC) investigation was done to confirm the
findings or in case of discordant findings on the
124I-PET
scan and
131I-WBS. If no abnormal uptake was seen on the
PET scan and
131I-WBS, additional radiologic imaging
(MRI, US), with or without FNAC, and fluorodeoxyglucose
(FDG) PETwere also performed to detect local or metastatic
disease and/or used as a follow-up diagnostic tool.
Results
From December 2005 until April 2007, 20 consecutive
patients with advanced DTC were included in this prospec-
tive study. The group consisted of ten women and ten men,
median age of 67 years (range 18–85 years). Individual
patient characteristics and the findings on the
124I PET scan
and
131I-WBS are summarised in Table 1.
Physiological uptake of
124I was observed in the salivary
glands, esophagus, gastrointestinal tract and bladder as it is
also normally seen on the
131I scans.
124I-PET vs diagnostic
131I-WBS
Eleven patients (no. 1–11) showed uptake on the
124I-PET
scan. In only three of them (no. 1–3) was the uptake also
observed on the diagnostic
131I scan, but the uptake was
clearer and the abnormalities were more extensive on the
124I-PET scan (Fig. 2). In nine patients (no. 12–20), no
uptake was observed on both the scans. Results of
additional radiologic imaging (MRI and/or US–FNAC)
are also listed in Table 1.
It has also been noticed that the Tgoff level (after
endogenous TSH stimulation) was not detectable
(<0.30 ng/ml, TSH >30 mU/L) without the presence of
Tg antibodies in five (Table 1, no. 5, 8, 12, 13, 20) of the 20
Fig. 2 This patient (no. 1)
showed a clearly visible lesion
in the cervical vertebrae on the
124I-PET (a, arrow), comparable
with the lesion visible on the
post-treatment
131I-WBS
(c, arrow). This lesion was
vaguely visible on the diagnos-
tic
131I-WBS (b, arrow).
Physiologic uptake in the
esophagus, gastrointestinal tract
and bladder is observed on the
124I-PET
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lesions on the
124I-PET (and post-treatment
131I scan)
confirmed by MRI. Diagnostic
131I-WBS was negative in
all five.
124I-PET vs post-treatment
131I-WBS
Nine (no. 1–9) out of the 11 patients with uptake on the
124I-PET scan had lesions which were also visible on the
post-treatment scan (Fig. 3). In two patients (no. 10, 11), no
uptake was observed on the post-treatment
131I scan and no
anatomical localisation could be confirmed. FDG PET
showed, however, lesions in the costae and pelvis in patient
no. 11 (Fig. 4).
Two patients (no. 12, 13) showed uptake on the post-
treatment
131I scan, which was not visible on the
124I-PET
scan: In one, MRI confirmed the
131I uptake in the skull,
and in the other, no anatomical localisation could be found
for the
131I uptake in the pelvis region. In seven patients
(no. 14–20), no uptake was observed on both the scans. In
four of seven patients (no. 14–17), no lesions could be
found with MRI and/or US–FNAC; in one of these four
(no. 17), FDG-PET showed uptake in the lungs which was
confirmed by CT. One patient (no. 18) showed slightly
enlarged lymph node in the superior mediastinum on the
MRI which was not accessible for US-guided FNAC. In
two patients (no. 19, 20), MRI/US of the neck will be
obtained (due to patient delay). Results of additional
radiologic imaging are listed in Table 1.
Discussion
This pilot study showed that
124I-PET detected more
abnormalities in comparison to the diagnostic
131I-WBS,
but showed comparable findings with the post-treatment
131I-WBS. Eleven patients had positive
124I-PET scanning,
and only three had visible abnormalities with the low-dose
131I scan. Moreover,
124I-PET also showed abnormalities in
two of the five patients with undetectable Tg, while the
low-dose diagnostic
131I scan was negative in all five.
These findings suggest that
124I-PET better predicts the
outcome of high-dose
131I treatment and would be better
suited as a diagnostic tool to base clinical decisions on such
as additional surgery or application of high dose
131I.
Therefore,
124I-PET should be performed before consider-
ing high-dose
131I treatment. A negative
124I-PET could
mean omitting
131I treatment, and further additional imaging
should be performed to detect (non-iodine avid) metastatic
disease.
Two patients (no. 12, 13) showed uptake in the skull and
pelvis region, respectively, on the post-treatment
131I-WBS
which was not visible on the
124I-PET. Possible explana-
tions for these findings might be the low dose of
124Ii n
which (small) lesions in the skull might be missed and
false-positive uptake of
131I in the bowel which could be
mistaken for abnormality.
OurresultsareinagreementwiththestudybyFreudenberg
et al. [17]. In their study, 12 patients with advanced DTC
underwent high-dose
131I-WBS,
124I-PET, CT, combined
Fig. 3 This patient (no. 6)
showed a clearly visible lesion
in the left lower neck region or
on the
124I-PET (a, arrow),
comparable with the lesion
visible on the post-treatment
131I-WBS (c, arrow). No uptake
was observed on the diagnostic
131I-WBS (b)
962 Eur J Nucl Med Mol Imaging (2008) 35:958–965124I-PET/CT, FDG-PET and US post-thyroidectomy during
routine clinical staging. The overall lesion detectability for
high-dose
131I-WBS was comparable with the
124I-PET, 83
vs 87%, respectively. Moreover, combined
124I-PET/CT
modality, which showed an overall lesion detectability of
100%, resulted in a change of staging in two patients and a
change in management in one.
It has been questioned why
124I-PET would be a suitable
diagnostic tool when blind treatment is given anyway in the
clinical practice. Blind treatment with high-dose
131Ii n
patients known with negative low-dose diagnostic
131I
scanning but with elevated Tg has been used as a
diagnostic, therapeutic and prognostic tool. Patients without
iodine accumulation on the post-treatment WBS, which
could be an indication for tumour dedifferentiation, had a
worse prognosis compared to those with a positive post-
treatment WBS [21]. Repeating high doses of
131I may bear
the risks in terms of long-term risk of secondary malignan-
cies. In addition, repeated long-lasting TSH stimulation
might have adverse effects on tumour growth. This aspect
of long-lasting TSH stimulation may be prevented when
performing the
124I-PET after rhTSH stimulation before the
decision of giving additional high-dose
131I. However,
comparative studies are needed to evaluate the yield of the
124I-PET under endogenous TSH stimulation and after
rhTSH stimulation.
Fig. 4 Clearly, uptake in the
right costae (arrow) and left hip
is seen on the FDG-PET (c)i n
patient no. 11, whereas the post-
treatment
131I-WBS (a) was
negative. The
124I-PET (b)
showed only uptake around the
femur prosthesis on the right
side, which is also observed on
the FDG-PET, which could be
explained by reactive tissue on
the MRI. The complementary
uptake of radioiodine and FDG
is also known as the flip-flop
phenomenon, which was first
described by Joensuu and
Ahonen [27]
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124I-PET would include the
better resolution of this tomographic method and the ease of
combining this with CT data to increase the diagnostic
value, as shown by Freudenberg et al. [17]. Moreover,
124I-
PET would allow more precise dosimetric calculations [25,
26, 28, 29], although that was not a focus of this study.
Another aspect which favours performing of
124I-PET
before blind high-dose
131I is the radiation dose. The
effective dose of
124I is in the same order of magnitude as
131I[ 10, 22–24]. The effective dose of
124I-iodide is
0.095 mSv/MBq with a thyroid uptake of 0% and increases
to1.5 mSv/MBq with a thyroid uptake of 35% [23]. The
total radiation exposure has been calculated at 7.0 mSv for
ad o s eo f7 4M B q
124I. The administered dose is comparable
to the dose administered for routine nuclear medicine scans.
However, the total radiation exposure of
124I is just a
fraction compared to the total radiation exposure of the
therapeutic dose of
131I (340 mSv for 5,550 MBq [23],
which was also mentioned in the study by Freudenberg
et al. [17].
The issue whether stunning is a real phenomenon and its
clinical relevance/consequence is debatable. Stunning effect
after (higher) diagnostic dose of
131I has been described and
discussed in the literature. The applied diagnostic
131I dose
could impair the ability of the residual thyroid carcinoma
tissue to accumulate the subsequently applied high-dose
131I dose. The degree of stunning probably depends on the
absorbed radiation dose and the time between the diagnos-
tic and therapeutic
131I dose.
Stunning was not seen with diagnostic
131I doses of
185 MBq (5 mCi) or lower [30, 31], whereas stunning was
frequently observed after a diagnostic dose of 370 MBq
(10 mCi)
131I[ 32]. There is also evidence that a short time
interval between the administration of the diagnostic and
therapeutic
131I dose may diminish the effect of stunning
[31]. Most authors who have described stunning adminis-
tered the therapeutic
131I dose several days after the
completion of the diagnostic
131I scan [32–35]. Stunning
is not seen when the therapeutic dose is administered within
several hours. Furthermore, the time interval between the
administration of a high dose of
131I and the performance of
a post-therapy WBS may influence the observation of
stunning [30, 36]. A longer time interval allows more time
for soft tissue clearance of
131I, which results in a higher
sensitivity of the post-therapy WBS. No stunning was seen
at the post-therapy
131I-WBS, performed 5–10 days after
doses of 1,110–3,700 MBq (30–100 mCi)
131Ia f t e r
74 MBq (2 mCi)) and 370 MBq (mCi) diagnostic scan [37].
In our study, we used a rather a low dose of
124I( 7 4M B q )
and a short interval (1 day) between the administration of the
diagnostic dose of
124I and the administration of the
therapeutic
131I dose and a long interval (10 days) between
the therapeutic
131I dose and the post-therapy
131I-WBS. If
stunning does exist after
124I, it is therefore unlikely to have
reduced the efficacy of
131I treatment in our study.
Iodine-124 is, however, poorly available with high costs,
but the advantages of
124I-PET could outweigh these
disadvantages and can lead to more clinical application in
the follow-up of DTC patients when
124I will become more
available.
Conclusions
In this study,
124I-PET proved to be a superior diagnostic
tool as compared to low-dose diagnostic
131I scans and
adequately predicted findings on subsequent high-dose
post-treatment
131I scans. In combination with the high
resolution and the possibilities to combine with CT, this
could lead to improved clinical decision making.
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